Systematic review reveals multi-omics strategies enhance biomarker discovery and optimize treatment in gastrointestinal cancers, indicating their potential in precision oncology.
Key Points
Multi-omics offers significant advances in early diagnosis and personalized treatment of gastrointestinal malignancies.
Analysis of 20 studies demonstrates superior diagnostic accuracy of multi-omics platforms over traditional biomarkers in detecting early-stage cancers.
Artificial intelligence enhances analysis of tumor microenvironment and aids in drug resistance recognition through multi-omics integration.
Findings underscore the importance of biomarker discovery and organoid modeling for individualized therapeutic strategies and improved patient outcomes.